

- Pseudoxanthoma elasticum, 364t, 365, 732, 1442
 PSI (Pneumonia Severity Index), 806
 Psittacosis, 1172–1173
 Psoas abscess, 852
 Psoralens, 361, 380, 389t, 391, 2177
 Psoriasis, **347**
 in ankylosing spondylitis, 2171
 clinical features of, 354t
 distribution of skin lesions, 340, 341t, 342f, 347t, 354t
 erythroderma, 353t, 354t
 morphology of skin lesions, 341t, 354t
 papules and plaques, 76e-1, 76e-1f, 343f, 347t, 353t
 diagnosis of, 354t
 drugs exacerbating, 378
 etiology of, 347
 genetic considerations in, 348
 guttate, 347
 histologic features of, 347t
 in HIV infection, 1263
 HLA gene association with, 373e-8t
 hypothermia in, 478e-1
 in IBD, 1958
 inflammatory mediators in, 372e-29t
 inverse, 347
 KIRs with, 372e-15t
 plaque-type, 347
 pustular
 vs. AGEP, 382
 clinical features of, 76e-1f, 347, 353, 356
 drugs exacerbating, 378
 treatment of, 96e-7, **348**, 348t, 354t, 387, 391
 Psoriatic arthritis, **2175**
 aortic aneurysm in, 1638
 aortitis in, 290e-3, 1638
 CASPAR criteria for, 2177, 2177t
 clinical features of, 348, 353, 2176–2177, 2176f
 definition of, 2175
 diagnosis of, 2177, 2177t
 epidemiology of, 2175–2176
 historic background of, 2175
 inflammasome activity in, 372e-8t
 KIRs with, 372e-15t
 pathogenesis of, 2176
 pathology of, 2176
 treatment of, 348t, 2177–2178
 Psoriatic spondylitis, 373e-8t
 PSORSIC3 gene, 1240t, 1241
 P-SPIKES, for communicating bad news, 57–58, 57t
 PSTPIT1 gene, 372e-8t, 2215
 PSV (pressure-support ventilation), 1742, 1743t.
 See also Mechanical ventilation
 PSVT. See Paroxysmal supraventricular tachycardia (PSVT)
 Psychiatric/psychological disorders, **2708**
 abdominal pain in, 106t
 in alcohol use disorder, 2724–2725
 anxiety disorders. See Anxiety disorders
 biology of, **465e-1**
 bipolar disorder. See Bipolar disorder
 classification of, 2708
 in cobalamin deficiency, 643
 vs. dementia, 2608
 depression. See Depression/depressive disorders
 eating and feeding disorders, **2719**
 fatigue in, 152
 in fibromyalgia, 2239
 in folate deficiency, 643
 gait disorders in, 164
 genetic considerations in, 465e-1–2, 465e-2t
 global considerations in, 17, 2708
 at high altitudes, 476e-5
 in the homeless, 2723
 inflammatory mechanisms in, 465e-4–5
 insomnia in, 190
 irritable bowel syndrome and, 1966
 mood disorders. See Mood disorders
 palpitations in, 254
 personality disorders, **2720**
 prevalence of, 2708
 primary care physician's responsibility in, 2708
 schizophrenia. See Schizophrenia
 signal transduction in, 465e-2–3, 465e-3f
 somatic symptom disorder, **2718**
 syncope in, 147, 148
 systems neuroscience of, 465e-3–4, 465e-4f, 465e-5t
 taste disorders in, 215
 in war veterans. See War veterans, neuropsychiatric illnesses in
 in Wilson's disease, 2519
 in women, 6e-5
 Psychogenic amnesia, 2608
 Psychogenic polydipsia, 2276, 2279
 Psychogenic seizures, 2551
 Psychosis(es). See also Schizophrenia
 alcohol-induced, 2725
 in Huntington's disease, 2622
 PCP-induced, 469e-4
 in PD, 2617
 postictal, 2558
 Psychosocial short stature, 2258
 Psychostimulants, 63, 65, 465e-5t
 Psychotherapy
 for anxiety disorders, 2709–2710
 for depression, 2716
 for panic disorder, 2709
 for phobic disorders, 2712
 for PTSD, 2713
 referral for, 2708
 for stress disease, 2712
 Psyllium, 1969, 1970t
 PT. See Prothrombin time (PT)
 PTCH gene mutations, 101e-6t, 500, 500f, 602
 PTEN, 89e-4
 PTEN gene mutations
 in autism spectrum disorders, 465e-1, 465e-2t
 in brain tumors, 599, 599t
 in breast cancer, 523
 cancers associated with, 101e-6t
 in Cowden's syndrome, 365, 2344
 in endometrial cancer, 596
 in lung cancer, 507t
 in melanoma, 496
 in thyroid cancer, 2305t
 Pterygium, 199
 PTH. See Parathyroid hormone (PTH)
 Pthiriasis palpebrum, 2746
 Pthirus pubis (pubic lice), 2745–2746
 PTH-related peptide, 313
 PTHrP. See Parathyroid hormone-related protein (PTHrP)
 PTNP22 gene mutations, 377e-3, 2140
 Ptoxis, 41e-1v, 207–208, 462e-2t
 PTPS (6-pyruvoyl-tetrahydropterin synthase) deficiency, 434e-2t
 PTSD. See Posttraumatic stress disorder (PTSD)
 Puberty
 definition of, 2357
 delayed. See Delayed puberty
 normal development during
 female, 2379, 2379t
 male, 2357–2358, 2357f
 precocious. See Precocious puberty
 Pubic lice (*Pthirus pubis*), 2745–2746
 Puborectal muscle, 265f
 PUBS (percutaneous umbilical blood sampling), 83e-4, 444
 Pudendal nerve terminal motor latency, in fecal incontinence, 1975
 "Puff of smoke" lesion, 2568
 Pulmonary alveolar proteinosis (PAP), 1714
 Pulmonary angiography, 1634, 1666–1667
 Pulmonary arterial hypertension (PAH), **1658**.
 See also Pulmonary hypertension
 conditions associated with, 1658
 in connective tissue disease, 1658
 diagnosis of, 47e-4, 308e-18f
 familial, 87e-3, 87e-3t
 in HIV infection, 1255, 1658
 idiopathic (primary), 271e-9f, 271e-9v, 1658
 pathogenesis of, 1655, 1656f, 1657t
 portal hypertension and, 1658
 in sarcoidosis, 2207
 in systemic sclerosis, 1658, 2161, 2164
 systems biology applied to, 87e-3, 87e-3t
 treatment of, 320e-1t, 1659–1660, 1660t
 Pulmonary artery, response to hypoxia, 248
 Pulmonary artery catheter
 in cardiogenic shock, 1760
 complications of, 1734
 in pulmonary edema, 1763
 in shock patient, 1747
 Pulmonary artery wedge pressure, 1444
 Pulmonary capillary wedge pressure
 in cardiogenic shock, 1759
 in pulmonary hypertension, 1657
 in sepsis/septic shock, 1755
 in shock, 1746, 1748t
 Pulmonary edema, **47e-4**
 cardiogenic, 47e-4, 1763
 chest radiography in, 47e-5, 308e-7f
 cyanosis in, 249
 diagnosis of, 1763
 differential diagnosis of, 47e-5
 dyspnea in, 47e-2t, 47e-4
 etiology of, 47e-5t
 hemodynamic patterns in, 1762t
 high-altitude. See High-altitude pulmonary edema (HAPE)
 in malaria, 1374, 1381
 noncardiogenic, 47e-4, 47e-5t, 1763
 pathophysiology of, 47e-4, 306e-3
 physical examination in, 47e-5, 1662
 reexpansion, 1764
 treatment of, 1761f, 1763
 in upper airway obstruction, 1764
 Pulmonary embolism (PE), **1631**
 adequacy of ventilation in, 306e-3
 after subarachnoid hemorrhage, 1787
 in burn patient, 166e-2
 catheter-based therapies for, 296e-5
 chest pain in, 96t, 97–98
 classification of, 1632
 diagnosis of
 blood tests, 1632
 cardiac biomarkers, 1594, 1633
 chest CT, 1633, 1633f
 chest radiograph, 101, 1633
 clinical decision rules, 1632t
 clinical evaluation, 1632
 clinical pearls, 1632
 CT, 308e-17f, 1664
 ECG, 101, 269e-11f, 1633
 echocardiography, 1634
 imaging algorithms, 1632f, 1634f
 lung scan, 1633–1634
 MRI, 1634
 pulmonary angiography, 1634, 1667–1668
 scintigraphic imaging, 1664
 Wells clinical prediction rule, 24t
 dyspnea in, 47e-2t, 47e-4, 1632
 epidemiology of, 743
 hemoptysis in, 100, 246
 in HIV infection, 1262
 incidence of, 274, 740
 in mitral stenosis, 1540
 nonthrombotic, 1632
 paraneoplastic, 613
 pathophysiology of, 1631–1632
 pleural effusion in, 1717
 postmenopausal hormone therapy and, 2384t
 in pregnancy, 47
 prevention of, 1636–1637, 1637t
 right ventricular dysfunction in, 270e-7, 1635
 risk stratification in, 1634
 septic, 958, 958f
 treatment of
 algorithm for, 1634f
 anticoagulants, 1634–1635, 1635t
 catheter-directed therapy, 1636
 duration of anticoagulation, 1635–1636
 emotional support, 1636
 fibrinolysis, 1636
 inferior vena cava filter, 1636
 in massive PE, 1636
 pulmonary embolectomy, 1636
 pulmonary thromboendarterectomy, 1636
 ventilation-perfusion heterogeneity in, 306e-4